Data / Drug companies / Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc.: 382 products in the FDA NDC directory, labeler code 0143
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hikma Pharmaceuticals USA Inc. (labeler code 0143) lists 382 products in the FDA National Drug Code Directory, covering 142 finished drugs by generic name. By type: 382 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 22, 2026.
The request: Watch Hikma Pharmaceuticals USA Inc. (FDA labeler code 0143): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0143
- Products in commercial distribution
- 382
- Packages
- 435
- Finished drugs by generic name
- 142
- Prescription products
- 382
- Over the counter products
- 0
- Controlled substance products
- Schedule II 3, Schedule III 7, Schedule IV 8
- Flagged as original packager
- 365 of 365 products that carry the flag
- Started marketing in the last 12 months
- 19
- Products with a marketing end date set
- 2
- Earliest marketing start
- October 20, 1971
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 323 | 84.6% |
| New drug applications (NDA) | 48 | 12.6% |
| Biologics (BLA) | 6 | 1.6% |
| Other unapproved drugs | 4 | 1% |
| Authorized generics (NDA) | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 382 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 132 | 34.6% |
| Injection, solution | 96 | 25.1% |
| Injection, powder, for solution | 56 | 14.7% |
| Injection, powder, lyophilized, for solution | 55 | 14.4% |
| Tablet | 16 | 4.2% |
| Powder, for suspension | 6 | 1.6% |
| Solution | 5 | 1.3% |
| Tablet, film coated | 5 | 1.3% |
| Capsule | 4 | 1% |
| Injection, solution, concentrate | 3 | 0.8% |
| Tablet, coated | 2 | 0.5% |
| Injection, suspension | 1 | 0.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Daptomycin | 0143-9456 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | October 22, 2026 |
| Meropenem | 0143-9485 | Injection, powder, for solution | Generic drugs (ANDA) | August 25, 2026 |
| Meropenem | 0143-9486 | Injection, powder, for solution | Generic drugs (ANDA) | June 8, 2026 |
| Epinephrine | 0143-9476 | Injection | Generic drugs (ANDA) | June 8, 2026 |
| Acetylcysteine | 0143-9433 | Injection, solution | Generic drugs (ANDA) | March 31, 2026 |
| Colistimethate | 0143-9443 | Injection, powder, for solution | Generic drugs (ANDA) | March 4, 2026 |
| Carboprost Tromethamine | 0143-9442 | Solution | Generic drugs (ANDA) | March 3, 2026 |
| Dexmedetomidine Hydrochloride | 0143-9198 | Injection, solution | Generic drugs (ANDA) | March 3, 2026 |
| Daptomycin | 0143-9455 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | February 25, 2026 |
| Xtrenbo | 0143-9166 | Injection | Biologics (BLA) | January 8, 2026 |
| Enoby | 0143-9165 | Injection | Biologics (BLA) | January 8, 2026 |
| Daptomycin | 0143-9445 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | December 11, 2025 |
| Ropivacaine Hydrochloride | 0143-9266 | Injection | Generic drugs (ANDA) | November 18, 2025 |
| Ropivacaine Hydrochloride | 0143-9265 | Injection | Generic drugs (ANDA) | November 18, 2025 |
| Ropivacaine Hydrochloride | 0143-9264 | Injection | Generic drugs (ANDA) | November 18, 2025 |
| Ropivacaine Hydrochloride | 0143-9263 | Injection | Generic drugs (ANDA) | November 18, 2025 |
| Ropivacaine Hydrochloride | 0143-9197 | Injection, solution | Generic drugs (ANDA) | November 7, 2025 |
| Ropivacaine Hydrochloride | 0143-9196 | Injection, solution | Generic drugs (ANDA) | November 7, 2025 |
| Ropivacaine Hydrochloride | 0143-9195 | Injection, solution | Generic drugs (ANDA) | November 7, 2025 |
| Cefepime Hydrochloride | 0143-9478 | Injection, powder, for solution | Generic drugs (ANDA) | October 31, 2025 |
| Cefepime Hydrochloride | 0143-9477 | Injection, powder, for solution | Generic drugs (ANDA) | October 31, 2025 |
| Starjemza | 0143-9171 | Injection | Biologics (BLA) | October 27, 2025 |
| Starjemza | 0143-9170 | Injection | Biologics (BLA) | October 27, 2025 |
| Starjemza | 0143-9169 | Injection | Biologics (BLA) | October 27, 2025 |
| Starjemza | 0143-9168 | Injection | Biologics (BLA) | October 27, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.